Market Rumors: Valeant Pharmaceuticals, Santander, Ardagh
After shelling out $19 billion on 40 acquisitions since 2008, Valeant Pharmaceuticals International Inc. is abandoning its aggressive growth via acquisition strategy to focus on reducing debt and boosting its stock...To view the full article, register now.
Already a subscriber? Click here to view full article